{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:13:50Z","timestamp":1789096430981,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.eclinm.2024.102579","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T05:18:06Z","timestamp":1712380686000},"page":"102579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial"],"prefix":"10.1016","volume":"71","author":[{"given":"Zixiang","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixian","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eclinm.2024.102579_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102579_bib2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1053\/j.gastro.2017.08.023","article-title":"Epidemiology of esophageal squamous cell carcinoma","volume":"154","author":"Abnet","year":"2018","journal-title":"Gastroenterology"},{"issue":"9864","key":"10.1016\/j.eclinm.2024.102579_bib3","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","article-title":"Oesophageal carcinoma","volume":"381","author":"Pennathur","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102579_bib4","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1007\/s12328-020-01237-x","article-title":"Epidemiology of esophageal cancer: update in global trends, etiology and risk factors","volume":"13","author":"Uhlenhopp","year":"2020","journal-title":"Clin J Gastroenterol"},{"issue":"27","key":"10.1016\/j.eclinm.2024.102579_bib5","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial","volume":"36","author":"Yang","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102579_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"New Engl J Med"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102579_bib7","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10302","key":"10.1016\/j.eclinm.2024.102579_bib8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.eclinm.2024.102579_bib9","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102579_bib10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.eclinm.2024.102579_bib11","series-title":"NCCN clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers. Version 4","year":"2022"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102579_bib12","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study","volume":"21","author":"Huang","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102579_bib13","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"J\u00a0Am Med Assoc"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102579_bib14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/cac2.12119","article-title":"Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma","volume":"40","author":"Zhang","year":"2020","journal-title":"Cancer Commun"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102579_bib15","first-page":"98","article-title":"Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma","volume":"2","author":"Wang","year":"2022","journal-title":"J\u00a0Natl Cancer Cent"},{"key":"10.1016\/j.eclinm.2024.102579_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.humpath.2020.11.001","article-title":"Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey","volume":"108","author":"Saliba","year":"2021","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102579_bib17","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/annonc\/mdw010","article-title":"A\u00a0randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction","volume":"27","author":"Klevebro","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102579_bib18","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy","volume":"7","author":"Pataer","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"issue":"23","key":"10.1016\/j.eclinm.2024.102579_bib19","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2013.53.6532","article-title":"Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901","volume":"32","author":"Mariette","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102579_bib20","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-17-2439","article-title":"Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma","volume":"24","author":"Huang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102579_bib21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ijc.33976","article-title":"Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, phase 2 study","volume":"151","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102579_bib22","article-title":"Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma","volume":"10","author":"Yang","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102579_bib23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eclinm.2024.102579_bib24","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.2147\/OTT.S132756","article-title":"Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma","volume":"10","author":"Li","year":"2017","journal-title":"Oncotargets Ther"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102579_bib25","first-page":"245","article-title":"Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial","volume":"7","author":"Meng","year":"2022","journal-title":"Lancet Gastroenterol"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102579_bib26","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102579_bib27","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102579_bib28","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.21037\/jtd.2018.03.175","article-title":"Chinese expert consensus on mediastinal lymph node dissection in esophagectomy for esophageal cancer (2017 edition)","volume":"10","author":"Li","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"issue":"9829","key":"10.1016\/j.eclinm.2024.102579_bib29","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/S0140-6736(12)60516-9","article-title":"Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial","volume":"379","author":"Biere","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102579_bib30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/SLA.0b013e3182590603","article-title":"Outcomes after minimally invasive esophagectomy: review of over 1000 patients","volume":"256","author":"Luketich","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.eclinm.2024.102579_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy","author":"Topalian","year":"2023","journal-title":"Cancer Cell"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024001585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024001585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T21:51:22Z","timestamp":1760737882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024001585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":31,"alternative-id":["S2589537024001585"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102579","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102579","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102579"}}